Pharmacie van Achter SRL
Pharmacie van Achter reported total assets of 193,448 € at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jun 2026).
The score of Pharmacie van Achter shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -23 % Total assets -18 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmacie van Achter's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 01 Jul 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Pharmacie van Achter's financial analysis
- Solvency17.6%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmacie van Achter
Pharmacie van Achter's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0667.995.349
- VAT number
- BE0667995349
- Peppol
- Registered · 0208:0667995349 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Dec 2016
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmacie van Achter (SRL) has been based in Ixelles since 2016, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 1,068 € and equity of 33,960 €; its revenue is not published. Its solvency stands at 17.6%, below the median of its sector (37.8%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharmacie van Achter
Companies in the same business, of comparable size and area, outside its group.
- Quality Pharmaceutical Service Retail sale of pharmaceutical products La Bruyère · balance sheet 110,124 €
- Codema Pharma Retail sale of pharmaceutical products Brussels · balance sheet 375,959 €
- ELIN Wholesale of pharmaceutical and medical goods Herk-de-Stad · balance sheet 181,098 €
- Dynaderm Retail sale of pharmaceutical products Wavre · balance sheet 47,613 €
- Tannhauser Pharaescos Retail sale of pharmaceutical products Koekelberg · balance sheet 292,153 €
- Novaplex Retail sale of pharmaceutical products Modave · balance sheet 119,122 €
- Apotheek Herne Retail sale of pharmaceutical products Pajottegem · balance sheet 330,199 €
- Dynamo Medical Other non-specialised retail sale Kortrijk · balance sheet 25,094 €
Frequently asked questions about Pharmacie van Achter
What is the revenue of Pharmacie van Achter?
Pharmacie van Achter files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmacie van Achter?
In Belgium, the VAT number is the company number prefixed with BE: BE0667995349 for Pharmacie van Achter, if the company is VAT-registered. Its company number (CBE) is 0667.995.349.
Where is the registered office of Pharmacie van Achter?
According to the CBE register, the registered office of Pharmacie van Achter is in 1050 Ixelles.
What is the equity of Pharmacie van Achter?
At the close of the 2025 financial year, the equity of Pharmacie van Achter amounts to 33,960 €, a solvency of 17.6% of total assets.
Who manages Pharmacie van Achter?
The register lists 1 active mandates at Pharmacie van Achter. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmacie van Achter
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →